Results 211 to 220 of about 57,115 (246)

IRINOTECAN

Reactions Weekly, 2014
  +4 more sources

Irinotecan

Reactions Weekly, 2012
openaire   +2 more sources

Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer

Lung Cancer, 2022
Natalia Fernández, Xavier Quantin
exaly  

Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy

Frontiers in Cellular and Infection Microbiology, 2021
Wei Dou, Ruiyang Gao
exaly  

Whither Irinotecan?

Journal of Clinical Oncology, 2005
openaire   +2 more sources

Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs

Cancer Science, 2022
Hironobu Minami, Gérard Milano
exaly  

Irinotecan

Reactions Weekly, 2003
openaire   +3 more sources

Irinotecan

Reactions Weekly, 2005
openaire   +1 more source

Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05)

Annals of Oncology, 2015
M Kochi, Y Kakeji, N Matsuhashi
exaly  

Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview

International Journal of Molecular Sciences, 2020
Beata Marciniak, Mateusz Kciuk, Renata Kontek   +2 more
exaly